The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Bortezomib Mylan 3.5 mg powder for solution for injection

McDermott Laboratories Ltd., T/A Gerard LaboratoriesPA0577/191/001

Main Information

Trade NameBortezomib Mylan 3.5 mg powder for solution for injection
Active SubstancesBortezomib
Dosage FormPowder for solution for injection
Licence HolderMcDermott Laboratories Ltd., T/A Gerard Laboratories
Licence NumberPA0577/191/001

Group Information

ATC CodeL01XX Other antineoplastic agents
L01XX32 bortezomib


License statusAuthorised
Licence Issued17/05/2019
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See: Summary of Product Characteristics, section 4.2).
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back